CD49d expression in chronic lymphocytic leukemia: A prognostic parameter and a therapeutic target

Pietro Bulian, Gianluca Gaidano, Giovanni Del Poeta, Valter Gattei

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia is a progressive disease for which there is no curative chemotherapy regimen. Progression may be either a late or an early event. occurring after more than 15 years or within 5 years from diagnosis. Counseling and management should be personalized on individual risk of progression, usually assessed by clinical staging and by investigating the presence of well-established biological markers: mutational status of immunoglobulin heavy variable region (IGHV) genes, chromososomal alterations as detected by fluorescence in situ hybridization, and expression of ZAP-70 and CD38. Several additional factors have been so far proposed as putative prognosticators, with the aim to find more reliable and easily measurable markers. Two recent studies indicate that CD49d is an independent prognosticator for overall survival and time-to-treatment, and that its value may be even more powerful than ZAP-70, CD38 or IGHV mutational status. CD49d is easily measurable by simple flow cytometer testing and is a potential therapeutic target, thanks to the availability of natalizumab, a US FDA-approved humanized monoclonal antibody for treatment of multiple sclerosis and Crohn's disease.

Original languageEnglish
Pages (from-to)355-358
Number of pages4
JournalFuture Oncology
Volume4
Issue number3
DOIs
Publication statusPublished - Jun 2008

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Immunoglobulin Variable Region
Antibodies, Monoclonal, Humanized
Fluorescence In Situ Hybridization
Crohn Disease
Multiple Sclerosis
Counseling
Therapeutics
Biomarkers
Drug Therapy
Genes

Keywords

  • CD49d
  • Chronic lymphocytic leukemia
  • CLL
  • Natalizumab
  • Overall survival
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

CD49d expression in chronic lymphocytic leukemia : A prognostic parameter and a therapeutic target. / Bulian, Pietro; Gaidano, Gianluca; Del Poeta, Giovanni; Gattei, Valter.

In: Future Oncology, Vol. 4, No. 3, 06.2008, p. 355-358.

Research output: Contribution to journalArticle

@article{c460c03dccab4983b17632281fb6ecd0,
title = "CD49d expression in chronic lymphocytic leukemia: A prognostic parameter and a therapeutic target",
abstract = "Chronic lymphocytic leukemia is a progressive disease for which there is no curative chemotherapy regimen. Progression may be either a late or an early event. occurring after more than 15 years or within 5 years from diagnosis. Counseling and management should be personalized on individual risk of progression, usually assessed by clinical staging and by investigating the presence of well-established biological markers: mutational status of immunoglobulin heavy variable region (IGHV) genes, chromososomal alterations as detected by fluorescence in situ hybridization, and expression of ZAP-70 and CD38. Several additional factors have been so far proposed as putative prognosticators, with the aim to find more reliable and easily measurable markers. Two recent studies indicate that CD49d is an independent prognosticator for overall survival and time-to-treatment, and that its value may be even more powerful than ZAP-70, CD38 or IGHV mutational status. CD49d is easily measurable by simple flow cytometer testing and is a potential therapeutic target, thanks to the availability of natalizumab, a US FDA-approved humanized monoclonal antibody for treatment of multiple sclerosis and Crohn's disease.",
keywords = "CD49d, Chronic lymphocytic leukemia, CLL, Natalizumab, Overall survival, Prognosis",
author = "Pietro Bulian and Gianluca Gaidano and {Del Poeta}, Giovanni and Valter Gattei",
year = "2008",
month = "6",
doi = "10.2217/14796694.4.3.355",
language = "English",
volume = "4",
pages = "355--358",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - CD49d expression in chronic lymphocytic leukemia

T2 - A prognostic parameter and a therapeutic target

AU - Bulian, Pietro

AU - Gaidano, Gianluca

AU - Del Poeta, Giovanni

AU - Gattei, Valter

PY - 2008/6

Y1 - 2008/6

N2 - Chronic lymphocytic leukemia is a progressive disease for which there is no curative chemotherapy regimen. Progression may be either a late or an early event. occurring after more than 15 years or within 5 years from diagnosis. Counseling and management should be personalized on individual risk of progression, usually assessed by clinical staging and by investigating the presence of well-established biological markers: mutational status of immunoglobulin heavy variable region (IGHV) genes, chromososomal alterations as detected by fluorescence in situ hybridization, and expression of ZAP-70 and CD38. Several additional factors have been so far proposed as putative prognosticators, with the aim to find more reliable and easily measurable markers. Two recent studies indicate that CD49d is an independent prognosticator for overall survival and time-to-treatment, and that its value may be even more powerful than ZAP-70, CD38 or IGHV mutational status. CD49d is easily measurable by simple flow cytometer testing and is a potential therapeutic target, thanks to the availability of natalizumab, a US FDA-approved humanized monoclonal antibody for treatment of multiple sclerosis and Crohn's disease.

AB - Chronic lymphocytic leukemia is a progressive disease for which there is no curative chemotherapy regimen. Progression may be either a late or an early event. occurring after more than 15 years or within 5 years from diagnosis. Counseling and management should be personalized on individual risk of progression, usually assessed by clinical staging and by investigating the presence of well-established biological markers: mutational status of immunoglobulin heavy variable region (IGHV) genes, chromososomal alterations as detected by fluorescence in situ hybridization, and expression of ZAP-70 and CD38. Several additional factors have been so far proposed as putative prognosticators, with the aim to find more reliable and easily measurable markers. Two recent studies indicate that CD49d is an independent prognosticator for overall survival and time-to-treatment, and that its value may be even more powerful than ZAP-70, CD38 or IGHV mutational status. CD49d is easily measurable by simple flow cytometer testing and is a potential therapeutic target, thanks to the availability of natalizumab, a US FDA-approved humanized monoclonal antibody for treatment of multiple sclerosis and Crohn's disease.

KW - CD49d

KW - Chronic lymphocytic leukemia

KW - CLL

KW - Natalizumab

KW - Overall survival

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=47249112119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249112119&partnerID=8YFLogxK

U2 - 10.2217/14796694.4.3.355

DO - 10.2217/14796694.4.3.355

M3 - Article

C2 - 18518761

AN - SCOPUS:47249112119

VL - 4

SP - 355

EP - 358

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -